Researchers have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer’s cells resistant to cancer drugs. The findings show that some classes of drugs won’t work, and certain types of so-called kinase inhibitors like erlotinib—may be the most effective at treating non-small cell lung cancers with those DNA changes. Some kinase inhibitors block a...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Predicting which lung cancer drugs are most likely to work
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account